Medindia

X

30-Year Johnson & Johnson Veteran Joins ConforMIS' Renowned Executive Team

Wednesday, November 7, 2007 General News J E 4
Advertisement
BURLINGTON, Mass., Nov. 6 ConforMIS, Inc., a privatelyheld company that develops and commercializes minimally invasive medicaldevices for the treatment of osteoarthritis and joint damage, announced todaythat industry veteran, John Slamin, has been appointed to the ConforMISExecutive team as Vice President of Implant Engineering for the Knee.

Prior to joining ConforMIS, Mr. Slamin spent over thirty years as a memberof the Research and Development arm of Johnson & Johnson's OrthopaedicDivision, now DePuy, where he was responsible for the product developmentactivities that led to the P.F.C. Total Knee System and later the Sigma TotalKnee System.

"John brings an enormous amount of industry experience to the executiveteam and we look forward to his significant contributions to the Company,"said Patrick Hess, PhD, President & Chief Executive Officer of ConforMIS. "Webelieve this is an integral time for ConforMIS as we continue our mission toprovide minimally invasive, patient-specific implants that significantlyimprove bone preservation and reduce procedure and recovery times."

Mr. Slamin is a recipient of the Johnson Medal for outstanding Researchand Development achievements and has lectured extensively both in the U.S. aswell as internationally on total knee design, biomaterials and the future ofknee replacement in a changing environment. He was also responsible forcoordinating the design and development of the world's first fully integratedand implantable electronic knee in collaboration with Clifford W. Colwell, MDof SCORE in La Jolla, California. Mr. Slamin is a graduate of WentworthInstitute of Technology in Boston, Mass.

Mr. Slamin joins an established executive team that includes Patrick Hess,PhD, MBA, FACB, President & Chief Executive Officer; Daniel Steines, MD, MS,Senior Vice President, Research & Development; Edward Ross, Jr., MBA, SeniorVice President, Commercial; S. Michael Sharp, PhD, FASLM, Senior VicePresident, Regulatory and Clinical Affairs; and Jong Lee, MBA, Senior VicePresident, Marketing.

"What attracted me most to ConforMIS is its unique platform technologythat is truly redefining minimally invasive surgery and the concept ofpersonalized medicine," said Mr. Slamin. "I'm thrilled to be joining such anexperienced and prominent team and I look forward to immediately contributingto the company's continued growth in the marketplace."

About ConforMIS, Inc.

ConforMIS, Inc. is a privately held company incorporated in 2004 thatdevelops and commercializes medical devices for the treatment ofosteoarthritis and joint damages. The Company's novel and scaleable "image-to-implant" process is comprised of two related technology platforms.iFit(TM) Technology enables the creation of conforming, patient-specificimplants that are precisely sized and shaped to match the 3D topography of thepatient's anatomic bone surfaces. The iJig(TM) Instrumentation enables thecreation of novel disposable instrumentation that radically simplifies andimproves the surgical process.

Both platforms are supported by proprietary, intellectual propertyconsisting of more than 100 issued, allowed and pending patents or patentapplications that span imaging software, image processing, implant design,surgical techniques and instrumentation.

To date, ConforMIS has developed a comprehensive line of minimallytraumatic, bone and cartilage-preserving knee implants and instrumentationdesigned to address all stages of osteoarthritis, the most common reason forknee replacement surgery. Each of these devices has been cleared by the USFood and Drug Administration for marketing in the U.S.

This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.ConforMIS, Inc. Contact: Jong Lee Senior Vice President, Marketing 781-345-9107 jong.lee@conformis.com Media
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New TylenolEspanol.com Expands Access to Informati...
S
BioView and Transgenomic Enter Into Distribution A...